Search

Your search keyword '"Hembrough, Todd"' showing total 333 results
Start Over Author "Hembrough, Todd"
333 results on '"Hembrough, Todd"'

1. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies

Author

Toulmonde, Maud, Lucchesi, Carlo, Verbeke, Stéphanie, Crombe, Amandine, Adam, Julien, Geneste, Damien, Chaire, Vanessa, Laroche-Clary, Audrey, Perret, Raul, Bertucci, François, Bertolo, Frederic, Bianchini, Laurence, Dadone-Montaudie, Bérengère, Hembrough, Todd, Sweet, Steve, Kim, Yeoun Jin, Cecchi, Fabiola, Le Loarer, François, and Italiano, Antoine

Published
2020
Full Text
View/download PDF

2. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

Author

Toulmonde, Maud, Pulido, Marina, Ray-Coquard, Isabelle, Andre, Thierry, Isambert, Nicolas, Chevreau, Christine, Penel, Nicolas, Bompas, Emmanuelle, Saada, Esma, Bertucci, François, Lebbe, Celeste, Le Cesne, Axel, Soulie, Patrick, Piperno-Neumann, Sophie, Sweet, Stephen, Cecchi, Fabiola, Hembrough, Todd, Bellera, Carine, Kind, Michèle, Crombe, Amandine, Lucchesi, Carlo, Le Loarer, François, Blay, Jean-Yves, and Italiano, Antoine

Published
2019
Full Text
View/download PDF

3. Comparative Evaluation of Strategies for Quantifying Signaling Pathway Proteins in Ewing Sarcoma

Author

Applebaum, Mark A, Thomas, Dafydd G, Hembrough, Todd, Burrows, Jon, Horvai, Andrew E, Lawlor, Elizabeth R, and DuBois, Steven G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Pediatric, Cancer, Rare Diseases, Female, Humans, Male, Mass Spectrometry, Neoplasm Proteins, Paraffin Embedding, Sarcoma, Ewing, Signal Transduction, Ewing sarcoma, immunohistochemical analysis, protein expression, mass spectrometry, Medical Physiology, Pathology, Clinical sciences
Abstract

Targeted therapies are increasingly being evaluated for patients with Ewing sarcoma (EWS). Optimal strategies for quantifying key signaling proteins in EWS remain unclear. We sought to quantify tumor expression of signaling pathway proteins in EWS using 3 methodologies. A total of 46 blocks of formalin-fixed paraffin-embedded tissue were obtained from 40 patients with EWS. Tumor was evaluated for the expression of proteins in the insulin-like growth factor type 1 receptor (IGF-1R), epithelial growth factor receptor (EGFR), and mTOR pathways using standard immunohistochemical analysis (IHC), automated quantitative analysis (AQUA) immunohistochemical analysis, and mass spectrometry quantification. The mean age at diagnosis was 14 years (range, 1 to 49 y). About 67.5% were male and 57.5% had localized disease. Samples displayed a wide range of expression by AQUA: mean (range) IGF-1R=10,702 (393 to 14,424); EGFR=2750 (672 to 9798); and phosphatase and tensin homolog (PTEN)=2250 (251 to 6557). Mean IGF-1R expression by AQUA did not differ between standard IHC expression categories (low IHC=11,255; medium IHC=11,070; high IHC=11,023; P=0.98). Mean PTEN expression by AQUA was higher in the medium and high IHC categories (low IHC=1229; medium IHC=2715; high IHC=2940; P=0.064). Only 2 samples expressed EGFR by standard IHC. Mass spectrometry trended toward correlation with standard IHC but did not yield interpretable results in the majority of samples. This study demonstrates that the relative quantification of signaling protein expression in EWS is dependent on the methodology used. Optimization and validation of these tools are necessary before clinical application for risk stratification of patients or measurement of biomarker expression.

Published
2014

4. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase

Author

Schwartz, Sarit, Szeto, Chris, Tian, Yuan, Cecchi, Fabiola, Corallo, Salvatore, Calegari, Maria Alessandra, Di Bartolomeo, Maria, Morano, Federica, Raimondi, Alessandra, Fucà, Giovanni, Martinetti, Antonia, De Pascalis, Ivana, Martini, Maurizio, Belfiore, Antonino, Milione, Massimo, Orlandi, Armando, Barault, Ludovic, Barone, Carlo, de Braud, Filippo, Di Nicolantonio, Federica, Benz, Steve, Hembrough, Todd, and Pietrantonio, Filippo

Published
2019
Full Text
View/download PDF

5. Supplementary Data from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, primary, Kleppa, Marc-Jens, primary, Slattery, Scott D., primary, Anantha, Andy, primary, Cooper, Alan, primary, Hannink, Mark, primary, Schambach, Axel, primary, Dörrie, Anneke, primary, Kotlyarov, Alexey, primary, Gaestel, Matthias, primary, Hembrough, Todd, primary, Levine, Jedd, primary, Luther, Michael, primary, Stocum, Michael, primary, Stiles, Linsey, primary, Weinstock, David M., primary, Liesa, Marc, primary, and Kostura, Matthew J., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table S4 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, primary, Kleppa, Marc-Jens, primary, Slattery, Scott D., primary, Anantha, Andy, primary, Cooper, Alan, primary, Hannink, Mark, primary, Schambach, Axel, primary, Dörrie, Anneke, primary, Kotlyarov, Alexey, primary, Gaestel, Matthias, primary, Hembrough, Todd, primary, Levine, Jedd, primary, Luther, Michael, primary, Stocum, Michael, primary, Stiles, Linsey, primary, Weinstock, David M., primary, Liesa, Marc, primary, and Kostura, Matthew J., primary

Published
2023
Full Text
View/download PDF

7. Data from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, primary, Kleppa, Marc-Jens, primary, Slattery, Scott D., primary, Anantha, Andy, primary, Cooper, Alan, primary, Hannink, Mark, primary, Schambach, Axel, primary, Dörrie, Anneke, primary, Kotlyarov, Alexey, primary, Gaestel, Matthias, primary, Hembrough, Todd, primary, Levine, Jedd, primary, Luther, Michael, primary, Stocum, Michael, primary, Stiles, Linsey, primary, Weinstock, David M., primary, Liesa, Marc, primary, and Kostura, Matthew J., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figures from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, primary, Kleppa, Marc-Jens, primary, Slattery, Scott D., primary, Anantha, Andy, primary, Cooper, Alan, primary, Hannink, Mark, primary, Schambach, Axel, primary, Dörrie, Anneke, primary, Kotlyarov, Alexey, primary, Gaestel, Matthias, primary, Hembrough, Todd, primary, Levine, Jedd, primary, Luther, Michael, primary, Stocum, Michael, primary, Stiles, Linsey, primary, Weinstock, David M., primary, Liesa, Marc, primary, and Kostura, Matthew J., primary

Published
2023
Full Text
View/download PDF

11. Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, additional, Kleppa, Marc-Jens, additional, Slattery, Scott D., additional, Anantha, Andy, additional, Cooper, Alan, additional, Hannink, Mark, additional, Schambach, Axel, additional, Doerrie, Anneke, additional, Kotylarov, Alexey, additional, Gaestel, Matthias, additional, Hembrough, Todd, additional, Levine, Jedd, additional, Luther, Michael, additional, Stocum, Michael, additional, Stiles, Linsey, additional, Weinstock, David M., additional, Liesa, Marc, additional, and Kostura, Matthew J., additional

Published
2023
Full Text
View/download PDF

13. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

Author

Wong, Gabrielle S., Zhou, Jin, Liu, Jie Bin, Wu, Zhong, Xu, Xinsen, Li, Tianxia, Xu, David, Schumacher, Steven E., Puschhof, Jens, McFarland, James, Zou, Charles, Dulak, Austin, Henderson, Les, Xu, Peng, O’Day, Emily, Rendak, Rachel, Liao, Wei-li, Cecchi, Fabiola, Hembrough, Todd, Schwartz, Sarit, Szeto, Christopher, Rustgi, Anil K., Wong, Kwok-Kin, Diehl, J. Alan, Jensen, Karin, Graziano, Francesco, Ruzzo, Annamaria, Fereshetian, Shaunt, Mertins, Philipp, Carr, Steven A., Beroukhim, Rameen, Nakamura, Kenichi, Oki, Eiji, Watanabe, Masayuki, Baba, Hideo, Imamura, Yu, Catenacci, Daniel, and Bass, Adam J.

Published
2018
Full Text
View/download PDF

16. Abstract 2803: Pharmacokinetics and pharmacodynamics of the novel OMA1 activator BTM 3566 in a mouse model of diffuse large B-cell lymphoma

Author

Bagherzadeh, Azadeh, primary, Baker, Jennifer, additional, Bennett, Charlotte, additional, Lee, Mi-Young, additional, Pacheco, Natalia, additional, Patel, Bhavisha, additional, Stewart, Kevin, additional, Travers, Jon, additional, Stocum, Michael, additional, Hembrough, Todd, additional, and Kostura, Matthew, additional

Published
2023
Full Text
View/download PDF

17. CD-20-0047R2_Supplementary_Figure_5.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Author

Zhang, Qu, primary, Luo, Jia, primary, Wu, Song, primary, Si, Han, primary, Gao, Chen, primary, Xu, Wenjing, primary, Abdullah, Shaad E., primary, Higgs, Brandon W., primary, Dennis, Phillip A., primary, van der Heijden, Michiel S., primary, Segal, Neil H., primary, Chaft, Jamie E., primary, Hembrough, Todd, primary, Barrett, J. Carl, primary, and Hellmann, Matthew D., primary

Published
2023
Full Text
View/download PDF

18. Data from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

Author

Sanchez-Vega, Francisco, primary, Hechtman, Jaclyn F., primary, Castel, Pau, primary, Ku, Geoffrey Y., primary, Tuvy, Yaelle, primary, Won, Helen, primary, Fong, Christopher J., primary, Bouvier, Nancy, primary, Nanjangud, Gouri J., primary, Soong, Joanne, primary, Vakiani, Efsevia, primary, Schattner, Mark, primary, Kelsen, David P., primary, Lefkowitz, Robert A., primary, Brown, Karen, primary, Lacouture, Mario E., primary, Capanu, Marinela, primary, Mattar, Marissa, primary, Qeriqi, Besnik, primary, Cecchi, Fabiola, primary, Tian, Yuan, primary, Hembrough, Todd, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Larson, Steven M., primary, Pandit-Taskar, Neeta, primary, Schöder, Heiko, primary, Iacobuzio-Donahue, Christine A., primary, Ilson, David H., primary, Weber, Wolfgang A., primary, Berger, Michael F., primary, de Stanchina, Elisa, primary, Taylor, Barry S., primary, Lewis, Jason S., primary, Solit, David B., primary, Carrasquillo, Jorge A., primary, Scaltriti, Maurizio, primary, Schultz, Nikolaus, primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

19. Data from Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma

Author

Maron, Steven B., primary, Alpert, Lindsay, primary, Kwak, Heewon A., primary, Lomnicki, Samantha, primary, Chase, Leah, primary, Xu, David, primary, O'Day, Emily, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Cecchi, Fabiola, primary, Hembrough, Todd, primary, Schrock, Alexa, primary, Hart, John, primary, Xiao, Shu-Yuan, primary, Setia, Namrata, primary, and Catenacci, Daniel V.T., primary

Published
2023
Full Text
View/download PDF

20. Data from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Author

Zhang, Qu, primary, Luo, Jia, primary, Wu, Song, primary, Si, Han, primary, Gao, Chen, primary, Xu, Wenjing, primary, Abdullah, Shaad E., primary, Higgs, Brandon W., primary, Dennis, Phillip A., primary, van der Heijden, Michiel S., primary, Segal, Neil H., primary, Chaft, Jamie E., primary, Hembrough, Todd, primary, Barrett, J. Carl, primary, and Hellmann, Matthew D., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legends from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

Author

Sanchez-Vega, Francisco, primary, Hechtman, Jaclyn F., primary, Castel, Pau, primary, Ku, Geoffrey Y., primary, Tuvy, Yaelle, primary, Won, Helen, primary, Fong, Christopher J., primary, Bouvier, Nancy, primary, Nanjangud, Gouri J., primary, Soong, Joanne, primary, Vakiani, Efsevia, primary, Schattner, Mark, primary, Kelsen, David P., primary, Lefkowitz, Robert A., primary, Brown, Karen, primary, Lacouture, Mario E., primary, Capanu, Marinela, primary, Mattar, Marissa, primary, Qeriqi, Besnik, primary, Cecchi, Fabiola, primary, Tian, Yuan, primary, Hembrough, Todd, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Larson, Steven M., primary, Pandit-Taskar, Neeta, primary, Schöder, Heiko, primary, Iacobuzio-Donahue, Christine A., primary, Ilson, David H., primary, Weber, Wolfgang A., primary, Berger, Michael F., primary, de Stanchina, Elisa, primary, Taylor, Barry S., primary, Lewis, Jason S., primary, Solit, David B., primary, Carrasquillo, Jorge A., primary, Scaltriti, Maurizio, primary, Schultz, Nikolaus, primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

22. Supplemental Data File from Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma

Author

Maron, Steven B., primary, Alpert, Lindsay, primary, Kwak, Heewon A., primary, Lomnicki, Samantha, primary, Chase, Leah, primary, Xu, David, primary, O'Day, Emily, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Cecchi, Fabiola, primary, Hembrough, Todd, primary, Schrock, Alexa, primary, Hart, John, primary, Xiao, Shu-Yuan, primary, Setia, Namrata, primary, and Catenacci, Daniel V.T., primary

Published
2023
Full Text
View/download PDF

23. Figure S1 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

Author

Sanchez-Vega, Francisco, primary, Hechtman, Jaclyn F., primary, Castel, Pau, primary, Ku, Geoffrey Y., primary, Tuvy, Yaelle, primary, Won, Helen, primary, Fong, Christopher J., primary, Bouvier, Nancy, primary, Nanjangud, Gouri J., primary, Soong, Joanne, primary, Vakiani, Efsevia, primary, Schattner, Mark, primary, Kelsen, David P., primary, Lefkowitz, Robert A., primary, Brown, Karen, primary, Lacouture, Mario E., primary, Capanu, Marinela, primary, Mattar, Marissa, primary, Qeriqi, Besnik, primary, Cecchi, Fabiola, primary, Tian, Yuan, primary, Hembrough, Todd, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Larson, Steven M., primary, Pandit-Taskar, Neeta, primary, Schöder, Heiko, primary, Iacobuzio-Donahue, Christine A., primary, Ilson, David H., primary, Weber, Wolfgang A., primary, Berger, Michael F., primary, de Stanchina, Elisa, primary, Taylor, Barry S., primary, Lewis, Jason S., primary, Solit, David B., primary, Carrasquillo, Jorge A., primary, Scaltriti, Maurizio, primary, Schultz, Nikolaus, primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures S1-S3 from Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma

Author

Maron, Steven B., primary, Alpert, Lindsay, primary, Kwak, Heewon A., primary, Lomnicki, Samantha, primary, Chase, Leah, primary, Xu, David, primary, O'Day, Emily, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Cecchi, Fabiola, primary, Hembrough, Todd, primary, Schrock, Alexa, primary, Hart, John, primary, Xiao, Shu-Yuan, primary, Setia, Namrata, primary, and Catenacci, Daniel V.T., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Tables S1-S10 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

Author

Sanchez-Vega, Francisco, primary, Hechtman, Jaclyn F., primary, Castel, Pau, primary, Ku, Geoffrey Y., primary, Tuvy, Yaelle, primary, Won, Helen, primary, Fong, Christopher J., primary, Bouvier, Nancy, primary, Nanjangud, Gouri J., primary, Soong, Joanne, primary, Vakiani, Efsevia, primary, Schattner, Mark, primary, Kelsen, David P., primary, Lefkowitz, Robert A., primary, Brown, Karen, primary, Lacouture, Mario E., primary, Capanu, Marinela, primary, Mattar, Marissa, primary, Qeriqi, Besnik, primary, Cecchi, Fabiola, primary, Tian, Yuan, primary, Hembrough, Todd, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Larson, Steven M., primary, Pandit-Taskar, Neeta, primary, Schöder, Heiko, primary, Iacobuzio-Donahue, Christine A., primary, Ilson, David H., primary, Weber, Wolfgang A., primary, Berger, Michael F., primary, de Stanchina, Elisa, primary, Taylor, Barry S., primary, Lewis, Jason S., primary, Solit, David B., primary, Carrasquillo, Jorge A., primary, Scaltriti, Maurizio, primary, Schultz, Nikolaus, primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

26. TableS1.docx from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Author

Zhang, Qu, primary, Luo, Jia, primary, Wu, Song, primary, Si, Han, primary, Gao, Chen, primary, Xu, Wenjing, primary, Abdullah, Shaad E., primary, Higgs, Brandon W., primary, Dennis, Phillip A., primary, van der Heijden, Michiel S., primary, Segal, Neil H., primary, Chaft, Jamie E., primary, Hembrough, Todd, primary, Barrett, J. Carl, primary, and Hellmann, Matthew D., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Tables S1-S4 from Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma

Author

Maron, Steven B., primary, Alpert, Lindsay, primary, Kwak, Heewon A., primary, Lomnicki, Samantha, primary, Chase, Leah, primary, Xu, David, primary, O'Day, Emily, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Cecchi, Fabiola, primary, Hembrough, Todd, primary, Schrock, Alexa, primary, Hart, John, primary, Xiao, Shu-Yuan, primary, Setia, Namrata, primary, and Catenacci, Daniel V.T., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Data from MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Author

Guo, Robin, primary, Offin, Michael, primary, Brannon, A. Rose, primary, Chang, Jason, primary, Chow, Andrew, primary, Delasos, Lukas, primary, Girshman, Jeffrey, primary, Wilkins, Olivia, primary, McCarthy, Caroline G., primary, Makhnin, Alex, primary, Falcon, Christina, primary, Scott, Kerry, primary, Tian, Yuan, primary, Cecchi, Fabiola, primary, Hembrough, Todd, primary, Alex, Deepu, primary, Shen, Ronglai, primary, Benayed, Ryma, primary, Li, Bob T., primary, Rudin, Charles M., primary, Kris, Mark G., primary, Arcila, Maria E., primary, Rekhtman, Natasha, primary, Paik, Paul, primary, Zehir, Ahmet, primary, and Drilon, Alexander, primary

Published
2023
Full Text
View/download PDF

31. Abstract A07: BTM 3566, a novel activator of the mitochondrial stress response promotes robust therapeutic responses in vitro and in vivo in diffuse large B-cell lymphoma

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, additional, Kleppa, Marc-Jens, additional, Anantha, Andy, additional, Cooper, Alan, additional, Hannink, Mark, additional, Hembrough, Todd, additional, Levine, Jedd, additional, Luther, Michael, additional, Stocum, Michael, additional, Stiles, Linsey, additional, Liesa-Roig, Marc, additional, and Kostura, Matthew, additional

Published
2022
Full Text
View/download PDF

33. Abstract 3784: BTM-3655 co-opts mitochondrial quality control pathways to induce apoptosis, and complete tumor regression in DLBCL cell lines, xenografts and PDX models

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, additional, Kleppa, Marc-Jens, additional, Anantha, Andy, additional, Cooper, Alan, additional, Hembrough, Todd, additional, Levine, Jedd, additional, Luther, Michael, additional, Stocum, Michael, additional, Liesa-Roig, Marc, additional, and Kostura, Matt, additional

Published
2022
Full Text
View/download PDF

34. Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, additional, Kleppa, Marc-Jens, additional, Slattery, Scott D., additional, Anantha, Andy, additional, Cooper, Alan, additional, Hannink, Mark, additional, Schambach, Axel, additional, Dörrie, Anneke, additional, Kotlyarov, Alexey, additional, Gaestel, Matthias, additional, Hembrough, Todd, additional, Levine, Jedd, additional, Luther, Michael, additional, Stocum, Michael, additional, Stiles, Linsey, additional, Weinstock, David, additional, Liesa, Marc, additional, and Kostura, Matthew J., additional

Published
2022
Full Text
View/download PDF

36. Btm-3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in Vitro and In Vivo in Diffuse Large B-Cell Lymphoma

Author

Schwarzer, Adrian, primary, Oliveira, Matheus, additional, Kleppa, Marc-Jens, additional, Anantha, Andy, additional, Cooper, Alan, additional, Hannink, Mark, additional, Hembrough, Todd, additional, Levine, Jedd, additional, Luther, Michael, additional, Stocum, Michael, additional, Liesa-Roig, Marc, additional, and Kostura, Matthew, additional

Published
2021
Full Text
View/download PDF

38. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Author

Yao, Zhan, Yaeger, Rona, Rodrik-Outmezguine, Vanessa S., Tao, Anthony, Torres, Neilawattie M., Chang, Matthew T., Drosten, Matthias, Zhao, Huiyong, Cecchi, Fabiola, Hembrough, Todd, Michels, Judith, Baumert, Herv, Miles, Linde, Campbell, Naomi M., de Stanchina, Elisa, Solit, David B., Barbacid, Mariano, Taylor, Barry S., and Rosen, Neal

Subjects
Gene mutation -- Health aspects, Tumors -- Genetic aspects -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Zhan Yao [1]; Rona Yaeger [2]; Vanessa S. Rodrik-Outmezguine [1]; Anthony Tao [3]; Neilawattie M. Torres [1]; Matthew T. Chang [4, 5, 6]; Matthias Drosten [7]; Huiyong Zhao [1]; [...]

Published
2017
Full Text
View/download PDF

39. MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Author

Guo, Robin, primary, Offin, Michael, additional, Brannon, A. Rose, additional, Chang, Jason, additional, Chow, Andrew, additional, Delasos, Lukas, additional, Girshman, Jeffrey, additional, Wilkins, Olivia, additional, McCarthy, Caroline G., additional, Makhnin, Alex, additional, Falcon, Christina, additional, Scott, Kerry, additional, Tian, Yuan, additional, Cecchi, Fabiola, additional, Hembrough, Todd, additional, Alex, Deepu, additional, Shen, Ronglai, additional, Benayed, Ryma, additional, Li, Bob T., additional, Rudin, Charles M., additional, Kris, Mark G., additional, Arcila, Maria E., additional, Rekhtman, Natasha, additional, Paik, Paul, additional, Zehir, Ahmet, additional, and Drilon, Alexander, additional

Published
2021
Full Text
View/download PDF

40. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Author

Zhang, Qu, primary, Luo, Jia, additional, Wu, Song, additional, Si, Han, additional, Gao, Chen, additional, Xu, Wenjing, additional, Abdullah, Shaad E., additional, Higgs, Brandon W., additional, Dennis, Phillip A., additional, van der Heijden, Michiel S., additional, Segal, Neil H., additional, Chaft, Jamie E., additional, Hembrough, Todd, additional, Barrett, J. Carl, additional, and Hellmann, Matthew D., additional

Published
2020
Full Text
View/download PDF

43. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S

Author

Di Bartolomeo, Maria, primary, Raimondi, Alessandra, additional, Cecchi, Fabiola, additional, Catenacci, Daniel V.T., additional, Schwartz, Sarit, additional, Sellappan, Shankar, additional, Tian, Yuan, additional, Miceli, Rosalba, additional, Pellegrinelli, Alessandro, additional, Giommoni, Elisa, additional, Aitini, Enrico, additional, Spada, Francesca, additional, Rosati, Gerardo, additional, Marchet, Alberto, additional, Pucci, Francesca, additional, Zaniboni, Alberto, additional, Tamberi, Stefano, additional, Pressiani, Tiziana, additional, Sanna, Gianni, additional, Cantore, Maurizio, additional, Mosconi, Stefania, additional, Bolzoni, Paola, additional, Pinto, Carmine, additional, Landi, Lorenza, additional, Soto Parra, Hector Josè, additional, Cavanna, Luigi, additional, Corallo, Salvatore, additional, Martinetti, Antonia, additional, Hembrough, Todd A., additional, and Pietrantonio, Filippo, additional

Published
2020
Full Text
View/download PDF

44. Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

Author

Li, Weimin, primary, Wildsmith, Sophie, additional, Ye, Jiabu, additional, Si, Han, additional, Morsli, Nassim, additional, He, Philip, additional, Shetty, Jagdish, additional, Yovine, Alejandro Javier, additional, Holoweckyj, Nicholas, additional, Raja, Rajiv, additional, Real, Katia, additional, Scorer, Paul, additional, Hembrough, Todd, additional, Walker, Jill, additional, Zhang, Qu, additional, Mesia, Ricard, additional, Haddad, Robert I., additional, Licitra, Lisa F., additional, and Ferris, Robert L., additional

Published
2020
Full Text
View/download PDF

45. Overcoming hypoxia-induced functional suppression of NK cells

Author

Solocinski, Kristen, primary, Padget, Michelle R, additional, Fabian, Kellsye P, additional, Wolfson, Benjamin, additional, Cecchi, Fabiola, additional, Hembrough, Todd, additional, Benz, Stephen C, additional, Rabizadeh, Shahrooz, additional, Soon-Shiong, Patrick, additional, Schlom, Jeffrey, additional, and Hodge, James W, additional

Published
2020
Full Text
View/download PDF

47. Supplementary_Figure_1 – Supplemental material for Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S

Author

Bartolomeo, Maria Di, Raimondi, Alessandra, Cecchi, Fabiola, Catenacci, Daniel V.T., Schwartz, Sarit, Sellappan, Shankar, Tian, Yuan, Miceli, Rosalba, Pellegrinelli, Alessandro, Giommoni, Elisa, Aitini, Enrico, Spada, Francesca, Rosati, Gerardo, Marchet, Alberto, Pucci, Francesca, Zaniboni, Alberto, Tamberi, Stefano, Pressiani, Tiziana, Sanna, Gianni, Cantore, Maurizio, Mosconi, Stefania, Bolzoni, Paola, Pinto, Carmine, Landi, Lorenza, Parra, Hector Josè Soto, Cavanna, Luigi, Corallo, Salvatore, Martinetti, Antonia, Hembrough, Todd A., and Pietrantonio, Filippo

Subjects
Medicine
Abstract

Supplemental material, Supplementary_Figure_1 for Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S by Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, Daniel V.T. Catenacci, Sarit Schwartz, Shankar Sellappan, Yuan Tian, Rosalba Miceli, Alessandro Pellegrinelli, Elisa Giommoni, Enrico Aitini, Francesca Spada, Gerardo Rosati, Alberto Marchet, Francesca Pucci, Alberto Zaniboni, Stefano Tamberi, Tiziana Pressiani, Gianni Sanna, Maurizio Cantore, Stefania Mosconi, Paola Bolzoni, Carmine Pinto, Lorenza Landi, Hector Josè Soto Parra, Luigi Cavanna, Salvatore Corallo, Antonia Martinetti, Todd A. Hembrough and Filippo Pietrantonio in Tumori Journal

Published
2020
Full Text
View/download PDF

50. Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue

Author

Hembrough Todd, Thyparambil Sheeno, Liao Wei-Li, Darfler Marlene M, Abdo Joseph, Bengali Kathleen M, Taylor Paul, Tong Jiefei, Lara-Guerra Humberto, Waddell Thomas K, Moran Michael F, Tsao Ming-Sound, Krizman David B, and Burrows Jon

Subjects
Formalin fixed, FFPE, EGFR, Gefitinib, Targeted therapy, Patient tissue, Quantitative, Personalized medicine, Molecular diagnostics, Non-small cell lung cancer, Medicine
Abstract

Abstract Background Analysis of key therapeutic targets such as epidermal growth factor receptor (EGFR) in clinical tissue samples is typically done by immunohistochemistry (IHC) and is only subjectively quantitative through a narrow dynamic range. The development of a standardized, highly-sensitive, linear, and quantitative assay for EGFR for use in patient tumor tissue carries high potential for identifying those patients most likely to benefit from EGFR-targeted therapies. Methods A mass spectrometry-based Selected Reaction Monitoring (SRM) assay for the EGFR protein (EGFR-SRM) was developed utilizing the Liquid Tissue®-SRM technology platform. Tissue culture cells (n = 4) were analyzed by enzyme-linked immunosorbent assay (ELISA) to establish quantitative EGFR levels. Matching formalin fixed cultures were analyzed by the EGFR-SRM assay and benchmarked against immunoassay of the non-fixed cultured cells. Xenograft human tumor tissue (n = 10) of non-small cell lung cancer (NSCLC) origin and NSCLC patient tumor tissue samples (n = 23) were microdissected and the EGFR-SRM assay performed on Liquid Tissue lysates prepared from microdissected tissue. Quantitative curves and linear regression curves for correlation between immunoassay and SRM methodology were developed in Excel. Results The assay was developed for quantitation of a single EGFR tryptic peptide for use in FFPE patient tissue with absolute specificity to uniquely distinguish EGFR from all other proteins including the receptor tyrosine kinases, IGF-1R, cMet, Her2, Her3, and Her4. The assay was analytically validated against a collection of tissue culture cell lines where SRM analysis of the formalin fixed cells accurately reflects EGFR protein levels in matching non-formalin fixed cultures as established by ELISA sandwich immunoassay (R2 = 0.9991). The SRM assay was applied to a collection of FFPE NSCLC xenograft tumors where SRM data range from 305amol/μg to 12,860amol/μg and are consistent with EGFR protein levels in these tumors as previously-reported by western blot and SRM analysis of the matched frozen tissue. In addition, the SRM assay was applied to a collection of histologically-characterized FFPE NSCLC patient tumor tissue where EGFR levels were quantitated from not detected (ND) to 670amol/μg. Conclusions This report describes and evaluates the performance of a robust and reproducible SRM assay designed for measuring EGFR directly in FFPE patient tumor tissue with accuracy at extremely low (attomolar) levels. This assay can be used as part of a complementary or companion diagnostic strategy to support novel therapies currently under development and demonstrates the potential to identify candidates for EGFR-inhibitor therapy, predict treatment outcome, and reveal mechanisms of therapeutic resistance.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results